How to get additional patients diagnosed and hit the estimated peak sales of $100 million for Zanvastro (zilganersen) became ...
The previously debated matter of how best to order primary and secondary endpoints was not solved but became moot as Ultragenyx Pharmaceutical Inc. disclosed that the phase III Angelman syndrome trial ...
Researchers at MD Anderson Cancer Center are about to start a clinical trial of psilocybin in the prevention of ...
GSK plc is moving further into antibody-drug conjugates, taking ex-China rights to Hutchmed Ltd.’s HMPL-A830 in a deal worth up to $1.295 billion, plus royalties. Of that, GSK is paying $110 million ...
Roche Holding AG filled a trispecific antibody-sized hole in its B-cell disease franchise by bringing in Simcere Zaiming Pharmaceutical Co. Ltd.’s SIM-0600, a preclinical CD79a/CD19/CD3-targeting ...
Researchers are exploring gene and cell therapies across a growing spectrum of diseases, from cancer and rare genetic disorders to neurological, autoimmune and cardiovascular conditions. As new ...
Mutations associated with autism spectrum disorder (ASD) alter the physical interactions between proteins. To understand how ...
Bloodstream infections are a leading cause of sepsis, a dysregulated immune response leading to systemic inflammation, organ failure and death, with substantial global morbidity and mortality. Rapid ...
Treatment with GLP-1 agonists beginning in late middle age protected cognitive and motor function and had beneficial effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results